Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

Citation

• Cao, J., Zhang, P., de Souza, P. L., Gao, B., Voskoboynik, M., Ji, D., . . . Xu, B. (2019). Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.. Journal of Clinical Oncology, 37(15_suppl), 3059. doi:10.1200/jco.2019.37.15_suppl.3059

Digital Object Identifier (doi)

• 10.1200/jco.2019.37.15_suppl.3059

Web Of Science Accession Number

Start Page

• 3059

End Page

• 3059

Volume

• 37

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2019

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Cao, J., Zhang, P., de Souza, P. L., Gao, B., Voskoboynik, M., Ji, D., . . . Xu, B. (2019). Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.. Journal of Clinical Oncology, 37(15_suppl), 3059. doi:10.1200/jco.2019.37.15_suppl.3059

Digital Object Identifier (doi)

• 10.1200/jco.2019.37.15_suppl.3059

Web Of Science Accession Number

Start Page

• 3059

End Page

• 3059

Volume

• 37

Issue

• 15_suppl

Place Of Publication